UY33886A - Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del vih - Google Patents

Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del vih

Info

Publication number
UY33886A
UY33886A UY0001033886A UY33886A UY33886A UY 33886 A UY33886 A UY 33886A UY 0001033886 A UY0001033886 A UY 0001033886A UY 33886 A UY33886 A UY 33886A UY 33886 A UY33886 A UY 33886A
Authority
UY
Uruguay
Prior art keywords
triterpenoids
modified
inhibiting activity
hiv maturation
compounds
Prior art date
Application number
UY0001033886A
Other languages
English (en)
Inventor
Liu Zheng
Swidorski Jacob
Sin Ny
Brian Lee Venables
Sing-Yuen Sit
Chen Jie
Nicholas A Meanwell
Chen Yan
Alicia Regueiro-Ren
Original Assignee
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware
Publication of UY33886A publication Critical patent/UY33886A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos que tienen propiedades farmacológicas y que afectan el aspecto biológico, sus composiciones farmacéuticas y métodos de uso. En particular, los triterpenoides C-17 y C-3 modificados que tienen una actividad antiviral única se proveen como inhibidores de la maduración del VIH, como se representa mediante los compuestos de las Fórmulas I, II y III. Estos compuestos son útiles para el tratamiento del VIH y del SIDA
UY0001033886A 2011-01-31 2012-01-31 Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del vih UY33886A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161437893P 2011-01-31 2011-01-31

Publications (1)

Publication Number Publication Date
UY33886A true UY33886A (es) 2012-07-31

Family

ID=45567147

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033886A UY33886A (es) 2011-01-31 2012-01-31 Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del vih

Country Status (24)

Country Link
US (3) US8846647B2 (es)
EP (1) EP2670765B1 (es)
JP (1) JP6001560B2 (es)
KR (1) KR101886467B1 (es)
CN (1) CN103429607B (es)
AR (1) AR085053A1 (es)
AU (1) AU2012212509B2 (es)
BR (1) BR112013019419A2 (es)
CA (1) CA2826113C (es)
CL (1) CL2013002185A1 (es)
CO (1) CO6751275A2 (es)
EA (1) EA022470B1 (es)
ES (1) ES2653847T3 (es)
IL (1) IL227678B (es)
MA (1) MA34909B1 (es)
MY (1) MY162186A (es)
PE (1) PE20141152A1 (es)
PT (1) PT2670765T (es)
SG (1) SG192144A1 (es)
TN (1) TN2013000321A1 (es)
TW (1) TWI628188B (es)
UY (1) UY33886A (es)
WO (1) WO2012106190A1 (es)
ZA (1) ZA201306546B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101665042B1 (ko) 2008-04-18 2016-10-11 리타 파마슈티컬스 잉크. 소염성 골격군을 포함하는 화합물 및 사용 방법
CN102083442B (zh) 2008-04-18 2014-08-13 里亚塔医药公司 抗氧化剂炎症调节剂:在c-17具有氨基和其它修饰的齐墩果酸衍生物
US7915402B2 (en) 2008-04-18 2011-03-29 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
LT2271658T (lt) 2008-04-18 2017-02-27 Reata Pharmaceuticals, Inc. Antioksidantai uždegimo moduliatoriai:oleanolio rūgšties c-17 patvirtinti dariniai
WO2012083306A2 (en) 2010-12-17 2012-06-21 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
EP2670764B1 (en) * 2011-01-31 2015-09-02 Bristol-Myers Squibb Company C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors
ME03469B (me) 2011-03-11 2020-01-20 Reata Pharmaceuticals Inc DERIVATI C4-MONOMETIL TRITERPENOIDA l POSTUPCI ZA NJIHOVU UPOTREBU
CN103814042B (zh) 2011-09-21 2015-08-19 百时美施贵宝公司 具有抗病毒活性的桦木酸衍生物
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
PL2841445T3 (pl) 2012-04-27 2017-10-31 Reata Pharmaceuticals Inc Pochodne 2,2-difluoropropionamidowe bardoksolonu metylu, formy polimorficzne oraz sposoby ich stosowania
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
KR20150043465A (ko) * 2012-08-15 2015-04-22 글락소 그룹 리미티드 화학 공정
HUE044126T2 (hu) 2012-09-10 2019-09-30 Reata Pharmaceuticals Inc Oleanolsav C17-alkándiil- és alkéndiil-származékai, és eljárás azok elõállítására
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
JP6186010B2 (ja) * 2013-02-06 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hiv成熟阻害活性を有するc−19修飾トリテルペノイド類
EA027861B1 (ru) 2013-02-25 2017-09-29 Бристол-Майерс Сквибб Компани C-3 алкил- и алкенилмодифицированные производные бетулиновой кислоты или их фармацевтические соли, противовирусная фармацевтическая композиция и фармацевтическая композиция для лечения вич на их основе
AU2015243500B2 (en) 2014-04-11 2017-03-30 ViiV Healthcare UK (No.4) Limited Triterpenoids with HIV maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
CA2967684A1 (en) * 2014-11-14 2016-05-19 VIIV Healthcare UK (No.5) Limited C17-aryl substituted betulinic acid analogs
US9969767B2 (en) 2014-11-14 2018-05-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
AU2016248235A1 (en) * 2015-04-14 2017-10-19 Viiv Healthcare Uk (No 4) Limited Crystalline forms of modified triterpenoid hydrochloride salts with HIV maturation inhibitor activity
WO2017017607A1 (en) 2015-07-28 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
BR112018001484A2 (pt) 2015-07-28 2018-09-11 Glaxosmithkline Ip No 2 Ltd “composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
WO2017025901A1 (en) * 2015-08-11 2017-02-16 Hetero Research Foundation Novel c28-analogues with c3-modifications of triterpene derivatives as hiv inhibitors
MX2018003569A (es) 2015-09-23 2018-11-29 Reata Pharmaceuticals Inc Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
WO2017051355A1 (en) 2015-09-24 2017-03-30 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
JP2018534322A (ja) 2015-11-20 2018-11-22 ヴィーブ ヘルスケア ユーケー(ナンバー4)リミテッド Hiv成熟阻害剤製剤
CN108699103A (zh) * 2016-01-20 2018-10-23 葛兰素史克知识产权第二有限公司 具有hiv成熟抑制活性的羽扇烷类的胺衍生物
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP3478703A1 (en) * 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
EP3661945B1 (en) 2017-08-04 2024-04-03 Ardelyx, Inc. Glycyrrhetinic acid derivatives for treating hyperkalemia
JP6926939B2 (ja) * 2017-10-23 2021-08-25 東京エレクトロン株式会社 半導体装置の製造方法
JP6977474B2 (ja) * 2017-10-23 2021-12-08 東京エレクトロン株式会社 半導体装置の製造方法
ES2970042T3 (es) 2018-04-24 2024-05-24 Viiv Healthcare Uk No 5 Ltd Compuestos con actividad inhibidora de la maduración del VIH
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
TW202045523A (zh) 2019-02-07 2020-12-16 美商阿德利克斯公司 用於治療高鉀血症之化合物及方法
ES2965305T3 (es) 2019-02-11 2024-04-12 Hetero Labs Ltd Nuevos derivados de triterpeno como inhibidores del VIH
GB2598300A (en) * 2020-08-21 2022-03-02 Univ Durham Cross-linking method and applications in bioconjugation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
EP1730163A4 (en) 2004-03-17 2009-12-30 Panacos Pharmaceuticals Inc Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
WO2008127364A2 (en) * 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
WO2009100532A1 (en) * 2008-02-14 2009-08-20 Virochem Pharma Inc. NOVEL 17ß LUPANE DERIVATIVES
US9067966B2 (en) * 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
PT2576586E (pt) * 2010-06-04 2015-10-23 Bristol Myers Squibb Co Amidas c-28 de derivados de ácido betulínico c-3 modificadas como inibidores de maturação de hiv
US8754068B2 (en) * 2010-06-04 2014-06-17 Bristol-Myers Squibb Company Modified C-3 betulinic acid derivatives as HIV maturation inhibitors

Also Published As

Publication number Publication date
AU2012212509B2 (en) 2016-01-21
TWI628188B (zh) 2018-07-01
ZA201306546B (en) 2015-03-25
CA2826113C (en) 2018-09-04
US20130035318A1 (en) 2013-02-07
MA34909B1 (fr) 2014-02-01
KR101886467B1 (ko) 2018-08-07
CA2826113A1 (en) 2012-08-09
CN103429607B (zh) 2016-02-17
CL2013002185A1 (es) 2013-12-27
EP2670765B1 (en) 2017-10-18
IL227678A0 (en) 2013-09-30
SG192144A1 (en) 2013-08-30
KR20140016279A (ko) 2014-02-07
JP2014503595A (ja) 2014-02-13
US20160151387A1 (en) 2016-06-02
WO2012106190A1 (en) 2012-08-09
US8846647B2 (en) 2014-09-30
NZ614871A (en) 2014-06-27
PE20141152A1 (es) 2014-09-22
PT2670765T (pt) 2018-01-08
EA201391127A1 (ru) 2013-12-30
EA022470B1 (ru) 2016-01-29
BR112013019419A2 (pt) 2019-12-03
CN103429607A (zh) 2013-12-04
CO6751275A2 (es) 2013-09-16
AU2012212509A1 (en) 2013-09-19
TW201309717A (zh) 2013-03-01
US20140343000A1 (en) 2014-11-20
MY162186A (en) 2017-05-31
JP6001560B2 (ja) 2016-10-05
ES2653847T3 (es) 2018-02-09
AR085053A1 (es) 2013-08-07
TN2013000321A1 (en) 2015-01-20
IL227678B (en) 2018-04-30
EP2670765A1 (en) 2013-12-11

Similar Documents

Publication Publication Date Title
UY33886A (es) Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del vih
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
EA201591545A1 (ru) C-3 алкил- и алкенил-модифицированные производные бетулиновой кислоты
GT201500088A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY35213A (es) Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico
EA201491531A1 (ru) C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
UY33946A (es) Derivados de c4-monometil triterpenoides y sus métodos de uso
ECSP18010481A (es) Composiciones de plinabulina
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201492016A1 (ru) C-17 бициклические амины тритерпеноидов с ингибиторной активностью созревания вич
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
ECSP14013215A (es) Compuestos novedosos
DOP2011000260A (es) Pirimidinas fusionadas
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CO2017003004A2 (es) Nuevas triazolo[4,5-d]pirimidinas
CO2018008157A2 (es) Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
CU20170102A7 (es) Nueva triterpenona c-3 con derivados de amida reversa c-17 como inhibidores de vih
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211006